Leo’s hand eczema research reveals scale and impact of condition

Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE)

The CHECK (patient-reported) and RWEAL (physician-reported) studies form the largest multinational CHE surveys conducted in the adult population. The latest findings are being presented at the European Society of Contact Dermatitis (ESCD) congress, held in Dresden, Germany.

CHE is found to be common in the general population, with around 5.6% of study participants self-reporting the condition in the last 12 months. Overall, 4.7% of participants reported physician-diagnosed CHE.